We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.09%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.09B
AUM Growth
-$133M
Cap. Flow
+$26.4M
Cap. Flow %
0.52%
Top 10 Hldgs %
35.29%
Holding
140
New
25
Increased
26
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$161M
2
BIIB icon
Biogen
BIIB
+$68.3M
3
BAX icon
Baxter International
BAX
+$66.2M
4
LLY icon
Eli Lilly
LLY
+$62.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$52.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$117M
2
PFE icon
Pfizer
PFE
+$71.4M
3
UNH icon
UnitedHealth
UNH
+$50.4M
4
NTRA icon
Natera
NTRA
+$46.7M
5
ETNB
89bio
ETNB
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALC icon
126
CalciMedica
CALC
$12.3M
– –
-297,382
Closed -$2.08M
HELP
127
Cybin Inc
HELP
$490M
– –
-141,745
Closed -$1.65M
ETNB
128
DELISTED
89bio
ETNB
– –
-3,658,869
Closed -$46.6M
EYPT icon
129
EyePoint Inc
EYPT
$988M
– –
-487,642
Closed -$1.71M
GLUE icon
130
Monte Rosa Therapeutics
GLUE
$1.83B
– –
-27,369
Closed -$208K
MRNA icon
131
Moderna
MRNA
$21.9B
– –
-82,550
Closed -$14.8M
PFE icon
132
Pfizer
PFE
$144B
– –
-1,393,600
Closed -$71.4M
PYXS icon
133
Pyxis Oncology
PYXS
$193M
– –
-848,252
Closed -$1.14M
SNY icon
134
CALL
Sanofi
SNY
$109B
– –
-100,000
Closed -$4.84M
SGEN
135
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-913,812
Closed -$117M
CINC
136
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-1,906,000
Closed -$23.4M
MACK
137
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-73,600
Closed -$843K
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2023 Portfolio in Review

As of Q1 2023, OrbiMed held 140 positions worth $5.09B, down 2.6% from $5.23B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q1 2023 filing shows 25 new, 26 increased, 29 reduced and 16 closed positions. Its largest new stake was Baxter International: 1,562,000 shares worth $63.4M. The largest sale was Seagen Inc. Common Stock, an estimated $117M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q1 2023 buy was Baxter International: 1,562,000 shares worth $63.4M.
  • OrbiMed added most to Enliven Therapeutics in Q1 2023, an estimated $161M increase.
  • OrbiMed's biggest Q1 2023 reduction was UnitedHealth, cutting an estimated $50.4M.
  • OrbiMed fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 35% of its $5.09B portfolio in Q1 2023.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2023.
  • OrbiMed's portfolio value fell 2.6% quarter-over-quarter to $5.09B.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.